Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 9Recurrence 5Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Acute 3Sarcoma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Vascular Neoplasms 1Triple Negative Breast Neoplasms 1Solitary Fibrous Tumors 1Solid Tumor Malignancy 1Smooth Muscle Tumor 1Sarcoma, Clear Cell 1Recurrent Squamous Cell Lung Carcinoma 1Pancreatic Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Nerve Sheath Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms, Adipose Tissue 1Neoplasm Metastasis 1Myoepithelioma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Liposarcoma, Myxoid 1Liposarcoma 1

Interventions

Cyclophosphamide 25Rituximab 22fludarabine 14Lenalidomide 10Vincristine 8Doxorubicin 8Prednisone 7Etoposide 7fludarabine phosphate 6Immunotherapy, Adoptive 5polatuzumab vedotin 4Cytarabine 4CT-P10 4Bendamustine Hydrochloride 4Antigens, CD19 4tocilizumab 3Gemcitabine 3Dexamethasone 3Carboplatin 3venetoclax 2veltuzumab 2prednylidene 2ofatumumab 2obinutuzumab 2ixazomib 2ibrutinib 2etoposide phosphate 2deltacortene 2carmustine, poliferprosan 20 drug combination 2acalabrutinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, B-Cell × selinexor × Clear all
NCT03147885 2025-09-29

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

Barbara Ann Karmanos Cancer Institute

Phase 1/2 Active not recruiting
43 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡